MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announces the presentation of results from a Phase IV, 595-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and safety of LUNESTA® brand eszopiclone in patients with insomnia and co-existing Generalized Anxiety Disorder (GAD). The results will be presented today at the annual meeting of the American College of Neuropsychopharmacology in Hollywood, Fla.
